Alchemyca Biotech | $2,500,000 | (Nov 22, 2024)
OneCell Diagnostics Inc. | $16,000,000 | (Nov 22, 2024)
Iontra Inc | $45,000,000 | (Nov 22, 2024)
Envisagenics
United States
- New York, NY
- 06/06/2024
- Series B
- Undisclosed Amount
Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence.
We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered.
Our breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.
- Industry Biotechnology Research
- Website https://www.envisagenics.com/
- LinkedIn https://www.linkedin.com/company/envisagenics/
Related People
Maria Luisa Pineda, PhD.Founder
United States -
New York, New York
Dr. Maria Luisa Pineda is a highly motivated, bilingual doctor with over 10 years of scientific experience, keen insight into business and organization building, excellent leadership skills balancing strategic thinking and logic.
Ambitious and looking forward to pairing a solid knowledge of science with playing a key role in decision-making, while adding significant value to a business.
For her undergraduate studies Maria was awarded an endowment of $2 million dollars from the Goizueta Foundation and was a NIH fellow with the Minority Access to Research Careers (MARC U*STAR) Award. Maria recently received her Ph.D. from the prestigious Watson School of Biological Sciences at Cold Spring Harbor Laboratory as an Arnold and Mabel Beckman graduate student and a William Randolph Hearst foundation scholar. After graduating, she acquired experience in investment of technology and life science startup companies at Canrock Ventures and Golden Seeds, LLC. Maria has recently started a bioinformatics start-up company spinout of Cold Spring Harbor Laboratory as the Co-founder and CEO.
Enveda | $130,000,000 | (Nov 22, 2024)
Shinami | $5,645,000 | (Nov 22, 2024)
DANNCE.ai | $2,600,000 | (Nov 22, 2024)
Trustero | $10,000,000 | (Nov 22, 2024)
Dote | $1,447,585 | (Nov 22, 2024)
CredFlow | $3,700,000 | (Nov 22, 2024)
Lighthouse (UK) | $370,000,000 | (Nov 22, 2024)
Faircraft | $15,800,000 | (Nov 22, 2024)
Clean Skin Club | $32,000,000 | (Nov 22, 2024)